Administrative approaches and leveraged resources for NSBCC Pilot Projects and Trans Alliance Challenges is described. The goal of the Pilot Projects program is to further the vision of the NSBCC at two levels - broaden our impact and influence with the local oncology community, and accelerate our Project goals. The goal of our Trans-Alliance activities programs are to assemble the best possible teams for meeting trans-Alliance challenges - whether meeting those challenges involves a competition or a cooperation with other CCNEs. For pilot projects, the NSBCC is partnering with the Broad Center for Regenerative l /ledicine and Stem Cell Research (Broad CRM), and with the Jonsson Comprehensive Cancer Center (JCCC), to develop a pilot project program that is designed to outreach to the broader, local community of cancer researchers and clinical oncologists. The Broad CRM and JCCC are providing at least $60,000 direct costs to match the $70,000 direct costs committed from CCNE funding, and are providing assistance in pilot project solicitations, selection, and oversight. Criteria for the selection of pilot projects are outlined. For trans-Alliance challenges and related activities, an administrative program is outlined for deciding how the NSBCC will respond to specific challenges. All NSBCC investigators, by choosing to be a part of the NSBCC, are committed towards working towards successfully executing of trans Alliance challenges, and so, depending upon the nature of the challenge, our approach is to put together the best team possible to meet that challenge. NSBCC director Heath, in consultation with co-Directors Dr. Phelps and Dr. Hood, as well as the NSBCC Internal Review Council, provide for oversight and administration of the Pilot Projects and Trans-Aliance Activities. The NSBCC External Advisory Board provides review expertise on the success of our programs.
Pilot Projects within the NSBCC are designed to help us extend the influence of our nanotechnology solutions to cancer biology and cancer clinical care problems into the broader, local oncology community. This is accomplished via a careful selection process of the right Projects, and by finding institutional partners who share our vision, and who provide substantial funds to match the CCNE resources.
|Thai, Minh; Graham, Nicholas A; Braas, Daniel et al. (2014) Adenovirus E4ORF1-induced MYC activation promotes host cell anabolic glucose metabolism and virus replication. Cell Metab 19:694-701|
|Masui, Kenta; Cavenee, Webster K; Mischel, Paul S (2014) mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab 25:364-73|
|Zhao, Jimmy L; Ma, Chao; O'Connell, Ryan M et al. (2014) Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis. Cell Stem Cell 14:445-59|
|Wong, Deborah J L; Rao, Amol; Avramis, Earl et al. (2014) Exposure to a histone deacetylase inhibitor has detrimental effects on human lymphocyte viability and function. Cancer Immunol Res 2:459-68|
|Robert, Lidia; Tsoi, Jennifer; Wang, Xiaoyan et al. (2014) CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res 20:2424-32|
|Nathanson, David A; Gini, Beatrice; Mottahedeh, Jack et al. (2014) Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-6|
|Chodon, Thinle; Comin-Anduix, Begoña; Chmielowski, Bartosz et al. (2014) Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res 20:2457-65|
|Ribas, Antoni; Tumeh, Paul C (2014) The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin Cancer Res 20:4982-4|
|Gini, Beatrice; Mischel, Paul S (2014) Greater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM. Cancer Discov 4:876-8|
|Akhavan, David; Pourzia, Alexandra L; Nourian, Alex A et al. (2013) De-repression of PDGFR* transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov 3:534-47|
Showing the most recent 10 out of 22 publications